News & Updates

Precision oncology is changing how clinicians approach cancer—from intervening earlier in high-risk disease to overcoming treatment resistance and targeting actionable molecular drivers.^1-4 Eli Lilly oncology developments build on these principles.

Tambotatug pelitecan (Tam-Peli), a novel B7-H3–targeting antibody–drug conjugate, delivers significant survival boost in relapsed small-cell lung cancer (SCLC) as compared with topotecan, according to the phase III TAISHAN-302 trial.

Results from the Italian RISP* trial presented at WCLC 2026 show improvement in smoking cessation rates following treatment with cytisine, a partial agonist of α4β2nicotinic acetylcholine receptors.

In the first-line treatment of patients with advanced HER2-mutant non-small cell lung cancer (NSCLC), trastuzumab deruxtecan (T-DXd) monotherapy confers a 6-month improvement in progression-free survival (PFS) compared with pembrolizumab plus chemotherapy, as shown in the phase III DESTINY-Lung04 trial.

Patients with chronic hepatitis B (CHB) infection who consume high levels of alcohol are at increased risk of hepatocellular carcinoma (HCC), as suggested in a retrospective study from China.

A report from Children’s Oncology Group (COG) AALL1731 study showed that paediatric patients with standard-risk (SR) B-cell acute lymphoblastic leukaemia (B-ALL) with undetectable minimal residual disease (MRD) at end of induction (EOI) by flow cytometry (FC) but not high-throughput sequencing (HTS) had inferior outcomes on chemotherapy alone, which were partially but not entirely mitigated by blinatumomab. In addition, outcomes of chemotherapy-only treatment among patients with MRD by HTS were not superior to those of patients with detectable MRD.

Some biomarkers of one-carbon metabolism are associated with toxicities induced by chemotherapy in patients with stage II‒III colorectal cancer (CRC), suggests a study.

Thoracic oncology is at a tipping point this year, coming off from highlights from both ELCC in March and ASCO in June. Notable updates from these conferences support the transition from broad, single agent strategies to innovative combination therapies and expanded use of known drugs for metastatic disease to early-stage setting.

While system navigation remains a challenge locally, global oncology has moved decisively beyond one-size-fits-all cytotoxic chemotherapy. Targeted therapy and immunotherapy now anchor treatment planning across breast, lung, and colorectal cancers, guided by the molecular and immune features of each tumor rather than its site of origin alone. Outcomes improve when treatment matches biology, and biology is now testable at the point of diagnosis. Benefit is increasingly measured not only in response rates, but in years of survival gained.

Cancer treatment has changed. And with it, comes a new reason to believe that a diagnosis does not have to be the end of the story.

There are few words that can change a person’s life in an instant.

“You have cancer.”

For many Filipinos, hearing those words still feels like receiving a death sentence.